Gene

MYC

MYC proto-oncogene, bHLH transcription factor

Explore in graph →CI-GENE-00015957HGNC:7553 ENSG00000136997 NCBI 4609 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (15)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–15 of 15 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR1 Amplification + MYC OverexpressionFGFR1 MYC1
Pazopanib	Lung Squamous Cell Carcinoma	Predictive	C	Supports Sensitivity Response

Cohorts

Alteration frequency by cohort (69)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved69 cohort rows (showing 19, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Metastatic Breast Cancer (MSK, Cancer Discovery 2022) breast_ink4_msk_2021	unmapped	Ssm	12	1,365

Literature

Linked publications (6)

25 per page, newest first.

pubmedPublishedShowing 1–6 of 6 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas.
· Blood · 2018 · PMID 30282799 · validated civic_curation pubmed
B Lymphoblastic Leukemia/Lymphoma With Burkitt-like Morphology and IGH/MYC Rearrangement: Report of 3 Cases in Adult Patients.
· Am J Surg Pathol · 2018 · PMID 29112016 · validated civic_curation pubmed
Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.
· Cancer Rep (Hoboken) · 2022 · PMID 34472720 · validated civic_curation pubmed
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
· Cancer Discov · 2014 · PMID 24302556 · validated civic_curation

MYC Fusion3
(diagnostic)	B-lymphoblastic Leukemia With MYC RearrangementUNRESOLVED	Diagnostic	B	Supports Positive	3	accepted	EID12381 In this 2018 study, the authors analyzed tumor samples from 13 patients diagnosed with IG-MYC–positive neoplasms exhibiting a precursor B-cell phenotype. This entity is molecularly distinct from class… (full text at CIViC) PMID 30282799 · Wagener et al., 2018 · Open in CIViC	civic
〃	B-lymphoblastic Leukemia With MYC RearrangementUNRESOLVED	Diagnostic	C	Supports Positive	3	accepted	EID12382 In this 2018 study, the authors described three rare adult cases of B-lymphoblastic leukemia/lymphoma (B-ALL/LBL) exhibiting Burkitt lymphoma-like morphology driven by isolated IGH/MYC translocations—… (full text at CIViC) PMID 29112016 · Li et al., 2018 · Open in CIViC	civic
〃	B-lymphoblastic Leukemia With MYC RearrangementUNRESOLVED	Diagnostic	C	Supports Positive	3	accepted	EID12383 In this 2022 study, the authors reported a rare case of atypical Burkitt leukemia/lymphoma (BL) in a 10-month-old infant, exhibiting overlapping features of both classical BL and its precursor form, p… (full text at CIViC) PMID 34472720 · Yoshida et al., 2022 · Open in CIViC	civic

MYC Fusion3

(diagnostic)

B-lymphoblastic Leukemia With MYC RearrangementUNRESOLVED

Diagnostic

Supports Positive

accepted

EID12381

In this 2018 study, the authors analyzed tumor samples from 13 patients diagnosed with IG-MYC–positive neoplasms exhibiting a precursor B-cell phenotype. This entity is molecularly distinct from class… (full text at CIViC)

PMID 30282799 · Wagener et al., 2018 · Open in CIViC

civic

〃

B-lymphoblastic Leukemia With MYC RearrangementUNRESOLVED

Diagnostic

Supports Positive

accepted

EID12382

In this 2018 study, the authors described three rare adult cases of B-lymphoblastic leukemia/lymphoma (B-ALL/LBL) exhibiting Burkitt lymphoma-like morphology driven by isolated IGH/MYC translocations—… (full text at CIViC)

PMID 29112016 · Li et al., 2018 · Open in CIViC

civic

〃

B-lymphoblastic Leukemia With MYC RearrangementUNRESOLVED

Diagnostic

Supports Positive

accepted

EID12383

In this 2022 study, the authors reported a rare case of atypical Burkitt leukemia/lymphoma (BL) in a 10-month-old infant, exhibiting overlapping features of both classical BL and its precursor form, p… (full text at CIViC)

PMID 34472720 · Yoshida et al., 2022 · Open in CIViC

civic

MET Amplification + MYC AmplificationMET MYC2
Capmatinib	Lung Adenocarcinoma	Predictive	C	Supports Resistance	3	submitted	EID11420 An 82-year old male (smoker: 60 pack-years) was diagnosed with lung adenocarcinoma. Initial tumor tissue testing revealed MET amplification (GCN = 13.5). The patient was enrolled in a phase 2 trial an… (full text at CIViC) PMID 36248327 · Choi et al., 2022 · Open in CIViC	civic
Capmatinib + ICX-101Sequential	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID11421 A patient diagnosed with lung adenocarcinoma had cells cultured to create patient-derived cell lines. Such cells exhibited MET amplification and showed overexpression of MYC. Capmatinib was administer… (full text at CIViC) PMID 36248327 · Choi et al., 2022 · Open in CIViC	civic

MET Amplification + MYC AmplificationMET MYC2

Capmatinib

Lung Adenocarcinoma

Predictive

Supports Resistance

submitted

EID11420

An 82-year old male (smoker: 60 pack-years) was diagnosed with lung adenocarcinoma. Initial tumor tissue testing revealed MET amplification (GCN = 13.5). The patient was enrolled in a phase 2 trial an… (full text at CIViC)

PMID 36248327 · Choi et al., 2022 · Open in CIViC

civic

Capmatinib + ICX-101Sequential

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

submitted

EID11421

A patient diagnosed with lung adenocarcinoma had cells cultured to create patient-derived cell lines. Such cells exhibited MET amplification and showed overexpression of MYC. Capmatinib was administer… (full text at CIViC)

PMID 36248327 · Choi et al., 2022 · Open in CIViC

civic

MYC Amplification2
(prognostic)	MedulloblastomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	5	submitted	EID7048 Group 3 medulloblastomas with MYC amplifications are often associated with large cell/anaplastic histology, young patients, and overall poor prognosis. PMID 15328187 · Lamont et al., 2004 · Open in CIViC	civic
Ibrutinib	Esophageal Carcinoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID6928 This study found the clinical BTK/ERBB2 kinase inhibitor, ibrutinib, downregulated ERK-mediated signal transduction, cMYC Ser-62 phosphorylation and levels of MYC protein, and elicited G1 cell cycle a… (full text at CIViC) PMID 28830912 · Chong et al., 2018 · Open in CIViC	civic

MYC Amplification2

(prognostic)

MedulloblastomaCURATED_BROADER

Prognostic

Supports Poor Outcome

submitted

EID7048

Group 3 medulloblastomas with MYC amplifications are often associated with large cell/anaplastic histology, young patients, and overall poor prognosis.

PMID 15328187 · Lamont et al., 2004 · Open in CIViC

civic

Ibrutinib

Esophageal Carcinoma

Predictive

Supports Sensitivity Response

submitted

EID6928

This study found the clinical BTK/ERBB2 kinase inhibitor, ibrutinib, downregulated ERK-mediated signal transduction, cMYC Ser-62 phosphorylation and levels of MYC protein, and elicited G1 cell cycle a… (full text at CIViC)

PMID 28830912 · Chong et al., 2018 · Open in CIViC

civic

MYC Overexpression3
Ganetespib	Esophageal Squamous Cell CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID10151 Collectively data from expression analysis of 102 esophageal squamous cell carcinoma (ESCC) sample tissues established MYC and HSP90 as potential targets with overexpression of MYC observed in over ha… (full text at CIViC) PMID 32308431 · Guan et al., 2020 · Open in CIViC	civic
JQ-1	Multiple Myeloma	Predictive	D	Supports Sensitivity Response	5	accepted	EID5505 BET inhibition by JQ1 downregulates MYC transcription, followed by genome-wide downregulation of Myc-dependent target genes. In experimental models of multiple myeloma, a Myc-dependent hematologic mal… (full text at CIViC) PMID 21889194 · Delmore et al., 2011 · Open in CIViC	civic
Cisplatin + Olaparib + PrexasertibCombination	Lung Small Cell Carcinoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID3003 A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexa… (full text at CIViC) PMID 28490518 · Sen et al., 2017 · Open in CIViC	civic

MYC Overexpression3

Ganetespib

Esophageal Squamous Cell CarcinomaALIAS

Predictive

Supports Sensitivity Response

submitted

EID10151

Collectively data from expression analysis of 102 esophageal squamous cell carcinoma (ESCC) sample tissues established MYC and HSP90 as potential targets with overexpression of MYC observed in over ha… (full text at CIViC)

PMID 32308431 · Guan et al., 2020 · Open in CIViC

civic

JQ-1

Multiple Myeloma

Predictive

Supports Sensitivity Response

accepted

EID5505

BET inhibition by JQ1 downregulates MYC transcription, followed by genome-wide downregulation of Myc-dependent target genes. In experimental models of multiple myeloma, a Myc-dependent hematologic mal… (full text at CIViC)

PMID 21889194 · Delmore et al., 2011 · Open in CIViC

civic

Cisplatin + Olaparib + PrexasertibCombination

Lung Small Cell Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID3003

A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexa… (full text at CIViC)

PMID 28490518 · Sen et al., 2017 · Open in CIViC

civic

MYC p.S146L1
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	C	Supports Oncogenicity	2	submitted	EID12696 MYC p.S146L, a recurrent substitution in the N-terminal transactivation domain near Myc Box 2, increased MYC–TRRAP binding in quantitative interaction assays and co-immunoprecipitation, with significa… (full text at CIViC) PMID 36018850 · Hinds et al., 2022 · Open in CIViC	civic

MYC p.S146L1

(oncogenic)

Malignant NeoplasmALIAS

Oncogenic

Supports Oncogenicity

submitted

EID12696

MYC p.S146L, a recurrent substitution in the N-terminal transactivation domain near Myc Box 2, increased MYC–TRRAP binding in quantitative interaction assays and co-immunoprecipitation, with significa… (full text at CIViC)

PMID 36018850 · Hinds et al., 2022 · Open in CIViC

civic

MYC Translocation1
(diagnostic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Diagnostic	A	Supports Positive	4	submitted	EID11809 MYC translocations, often (but not always) involving immunoglobulin loci, are common in DLBCL and one of two defining features of high-grade B-cell lymphoma with MYC and BCL2 rearrangements PMID 35653592 · Campo et al., 2022 · Open in CIViC	civic

MYC Translocation1

(diagnostic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Diagnostic

Supports Positive

submitted

EID11809

MYC translocations, often (but not always) involving immunoglobulin loci, are common in DLBCL and one of two defining features of high-grade B-cell lymphoma with MYC and BCL2 rearrangements

PMID 35653592 · Campo et al., 2022 · Open in CIViC

civic

BCL2 Translocation + MYC TranslocationMYC BCL21
(diagnostic)	High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements	Diagnostic	A	Supports Positive	4	submitted	EID11811 MYC and BCL2 rearrangements together are defining diagnostic features of this new entity PMID 35653592 · Campo et al., 2022 · Open in CIViC	civic

BCL2 Translocation + MYC TranslocationMYC BCL21

(diagnostic)

High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements

Diagnostic

Supports Positive

submitted

EID11811

MYC and BCL2 rearrangements together are defining diagnostic features of this new entity

PMID 35653592 · Campo et al., 2022 · Open in CIViC

civic

BCL2 Translocation + BCL6 Translocation + MYC TranslocationMYC BCL2 BCL61
(prognostic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Prognostic	C	Supports Poor Outcome	2	submitted	EID9813 In 2016 the WHO added a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed high-grade B-cell lymphoma with MYC AND [BCL2 OR BCL6] translocations. These represent less than 1… (full text at CIViC) PMID 28600333 · Friedberg, 2017 · Open in CIViC	civic

BCL2 Translocation + BCL6 Translocation + MYC TranslocationMYC BCL2 BCL61

(prognostic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Prognostic

Supports Poor Outcome

submitted

EID9813

In 2016 the WHO added a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed high-grade B-cell lymphoma with MYC AND [BCL2 OR BCL6] translocations. These represent less than 1… (full text at CIViC)

PMID 28600333 · Friedberg, 2017 · Open in CIViC

civic